| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Fate Therapeutics Inc (FATE) has 13 insiders with recent SEC Form 4 filings, including 5 buys and 8 sells. FATE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.89M | $8.31M | - | |
| CEO | 1.30M | $2.78M | - | |
| Other | 400.0K | $854.0K | - | |
| Dir | 110.0K | $234.8K | - | |
| CFO | 100.0K | $213.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2023 | Dulac Edward J III81 | Chief Financial Officer | Sell | 4,718 | $2.80 | $13,210.40 | -3.8% | -14.4% | +22.3% | |
| Aug 4, 2023 | Xu Yuan64 | Director | Sell | 632 | $3.71 | $2,344.72 | -6.4% | -40.8% | +24.1% | |
| Jul 5, 2023 | Powl Brian T.56 | Chief Commercial Officer | Sell | 3,854 | $4.87 | $18,768.98 | -8.6% | -62.1% | -34.8% | |
| Jul 5, 2023 | Dulac Edward J III81 | Chief Financial Officer | Sell | 5,182 | $4.83 | $25,029.06 | -4.0% | -62.1% | -34.8% | |
| Jun 14, 2023 | Xu Yuan64 | Director | Sell | 3,460 | $5.58 | $19,306.80 | -25.8% | -53.2% | -30.8% | |
| Apr 21, 2023 | Redmile Group, LLC | Director, 10% Owner | Buy | 276,639 | $6.17 | $1,705,829.02 | +1.1% | -28.5% | -22.8% | |
| Apr 18, 2023 | Chu Yu-Waye72 | Chief Medical Officer | Sell | 2,532 | $6.57 | $16,647.66 | -0.9% | -25.2% | -15.4% | |
| Apr 14, 2023 | Redmile Group, LLC | Director, 10% Owner | Sell | 302,339 | $5.84 | $1,765,659.76 | -2.3% | -18.1% | -4.0% | |
| Apr 14, 2023 | Redmile Group, LLC | Director, 10% Owner | Buy | 25,700 | $6.00 | $154,200.00 | +0.2% | -18.1% | -4.0% | |
| Jan 13, 2023 | Mendlein John50 | Director | Buy | 124,679 | $5.60 | $698,138.49 | +30.8% | +14.8% | -15.7% |